BioSpace News Archive

High prevalence of cancer across the globe, improving healthcare infrastructure, and increasing healthcare spending are some key factors expected to fuel market revenue growth.

As an emerging technology, close to insulin pumps, but with quicker drug delivery spells, wearable injectors have now become a preferred choice among the medical fraternity as well as the common people alike.

Factors that drive the growth of the global specialty PACS market include increasing investment in medical imaging, rising use of imaging equipment and increasing adoption of medical imaging health care IT solution.

Biocom California, the association representing the California life science industry, today announced that it has added Amy Butler, Ph.D., president of Biosciences at Thermo Fisher Scientific, to its board of directors and has appointed David H. Crean, Ph.D., managing partner of Coast Bioventures LLC, to its board of governors.

A team of physicians, led by neurosurgeon Dr. B.S. Harhangi from Erasmus Medical Center in Rotterdam, recently published a study demonstrating considerable relief for patients with herniated discs after using the MaxMoreSpine© System.

Adocia, a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced its fourth quarter financial results.

U.S. Pharmacopeia (USP), a global independent scientific organization, is seeking scientific input on new draft guidelines, “Analytical Procedures for mRNA Vaccine Quality.”

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent for multiple antineoplastic agents, was submitted in February 2022 (hereinafter referred to as the “Application for Partial Change”).

Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

AstraZeneca Canada has signed an agreement with the Government of Canada for the supply of 100,000 doses of Evusheld (tixagevimab co-packaged with cilgavimab), its long-acting antibody (LAAB) combination for the prevention (pre-exposure prophylaxis) of COVID-19 in those patient populations who require additional protection.